Neurobo Pharmaceuticals Stock Price Prediction
| NRBO Stock | USD 3.23 0.09 2.87% |
Oversold Vs Overbought
31
Oversold | Overbought |
Neurobo Pharmaceuticals stock price prediction is an act of determining the future value of Neurobo Pharmaceuticals shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of Neurobo Pharmaceuticals' future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of Neurobo Pharmaceuticals and does not consider all of the tangible or intangible factors available from Neurobo Pharmaceuticals' fundamental data. We analyze noise-free headlines and recent hype associated with Neurobo Pharmaceuticals, which may create opportunities for some arbitrage if properly timed.
Below are the key fundamental drivers impacting Neurobo Pharmaceuticals' stock price prediction:EPS Estimate Next Quarter (0.96) | EPS Estimate Current Year (3.50) | EPS Estimate Next Year (2.22) | Wall Street Target Price 36.5 | EPS Estimate Current Quarter (0.78) |
It is a matter of debate whether stock price prediction based on information in financial news can generate a strong buy or sell signal. We use our internally-built news screening methodology to estimate the value of Neurobo Pharmaceuticals based on different types of headlines from major news networks to social media. The Neurobo stock price prediction module provides an analysis of price elasticity to changes in media outlook on Neurobo Pharmaceuticals over a specific investment horizon. Using Neurobo Pharmaceuticals hype-based prediction, you can estimate the value of Neurobo Pharmaceuticals from the perspective of Neurobo Pharmaceuticals response to recently generated media hype and the effects of current headlines on its competitors.
This module is based on analyzing investor sentiment around taking a position in Neurobo Pharmaceuticals. This speculative approach is based exclusively on the idea that markets are driven by emotions such as investor fear and greed. The fear of missing out, i.e., FOMO, can cause potential investors in Neurobo Pharmaceuticals to buy its stock at a price that has no basis in reality. In that case, they are not buying Neurobo because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Neurobo Pharmaceuticals after-hype prediction price | USD 2.99 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Neurobo |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Neurobo Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Neurobo Pharmaceuticals After-Hype Price Prediction Density Analysis
As far as predicting the price of Neurobo Pharmaceuticals at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Neurobo Pharmaceuticals or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Neurobo Pharmaceuticals, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Neurobo Pharmaceuticals Estimiated After-Hype Price Volatility
In the context of predicting Neurobo Pharmaceuticals' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Neurobo Pharmaceuticals' historical news coverage. Neurobo Pharmaceuticals' after-hype downside and upside margins for the prediction period are 0.15 and 13.16, respectively. We have considered Neurobo Pharmaceuticals' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Neurobo Pharmaceuticals is dangerous at this time. Analysis and calculation of next after-hype price of Neurobo Pharmaceuticals is based on 3 months time horizon.
Neurobo Pharmaceuticals Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Neurobo Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Neurobo Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Neurobo Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.38 | 10.17 | 0.24 | 0.12 | 9 Events / Month | 10 Events / Month | In about 9 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
3.23 | 2.99 | 7.43 |
|
Neurobo Pharmaceuticals Hype Timeline
Neurobo Pharmaceuticals is now traded for 3.23. The entity has historical hype elasticity of -0.24, and average elasticity to hype of competition of 0.12. Neurobo is forecasted to decline in value after the next headline, with the price expected to drop to 2.99. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -7.43%, whereas the daily expected return is now at 0.38%. The volatility of related hype on Neurobo Pharmaceuticals is about 3100.61%, with the expected price after the next announcement by competition of 3.35. About 62.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.06. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Neurobo Pharmaceuticals recorded a loss per share of 2.46. The entity last dividend was issued on the 31st of December 2019. The firm had 1:8 split on the 21st of December 2023. Given the investment horizon of 90 days the next forecasted press release will be in about 9 days. Check out Neurobo Pharmaceuticals Basic Forecasting Models to cross-verify your projections.Neurobo Pharmaceuticals Related Hype Analysis
Having access to credible news sources related to Neurobo Pharmaceuticals' direct competition is more important than ever and may enhance your ability to predict Neurobo Pharmaceuticals' future price movements. Getting to know how Neurobo Pharmaceuticals' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Neurobo Pharmaceuticals may potentially react to the hype associated with one of its peers.
Neurobo Pharmaceuticals Additional Predictive Modules
Most predictive techniques to examine Neurobo price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Neurobo using various technical indicators. When you analyze Neurobo charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Neurobo Pharmaceuticals Predictive Indicators
The successful prediction of Neurobo Pharmaceuticals stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Neurobo Pharmaceuticals, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Neurobo Pharmaceuticals based on analysis of Neurobo Pharmaceuticals hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Neurobo Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Neurobo Pharmaceuticals's related companies. | 2023 | 2024 (projected) | Interest Debt Per Share | 0.04 | 0.038 | Revenue Per Share | 0.001242 | 0.001104 |
Story Coverage note for Neurobo Pharmaceuticals
The number of cover stories for Neurobo Pharmaceuticals depends on current market conditions and Neurobo Pharmaceuticals' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Neurobo Pharmaceuticals is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Neurobo Pharmaceuticals' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
View All Premium Stories
Neurobo Pharmaceuticals Short Properties
Neurobo Pharmaceuticals' future price predictability will typically decrease when Neurobo Pharmaceuticals' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Neurobo Pharmaceuticals often depends not only on the future outlook of the potential Neurobo Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Neurobo Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 5.1 M | |
| Cash And Short Term Investments | 22.4 M |
Check out Neurobo Pharmaceuticals Basic Forecasting Models to cross-verify your projections. To learn how to invest in Neurobo Stock, please use our How to Invest in Neurobo Pharmaceuticals guide.Note that the Neurobo Pharmaceuticals information on this page should be used as a complementary analysis to other Neurobo Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Complementary Tools for Neurobo Stock analysis
When running Neurobo Pharmaceuticals' price analysis, check to measure Neurobo Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurobo Pharmaceuticals is operating at the current time. Most of Neurobo Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Neurobo Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurobo Pharmaceuticals' price. Additionally, you may evaluate how the addition of Neurobo Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
Is Neurobo Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurobo Pharmaceuticals. If investors know Neurobo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurobo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.46) | Return On Assets (0.35) | Return On Equity (0.65) |
The market value of Neurobo Pharmaceuticals is measured differently than its book value, which is the value of Neurobo that is recorded on the company's balance sheet. Investors also form their own opinion of Neurobo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Neurobo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurobo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Neurobo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurobo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurobo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurobo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.